SIBCS 2025 | Professor Kun Wang: Precision Subtyping Drives a New Era of Neoadjuvant Therapy in Breast Cancer—Current Exploration and Future Outlook 

SIBCS 2025 | Professor Kun Wang: Precision Subtyping Drives a New Era of Neoadjuvant Therapy in Breast Cancer—Current Exploration and Future Outlook 

 The 20th Shanghai International Breast Cancer Symposium (SIBCS), hosted by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was held on November 13–15, 2025. During the “Hundred Schools of Thought” session, Professor Kun Wang from Guangdong Provincial People’s Hospital delivered an academic presentation titled “Guangdong Experience: Exploring Neoadjuvant Therapy in the New Era.” Following his talk, Oncology Frontier invited Professor Wang to elaborate on his team’s latest clinical progress in breast cancer neoadjuvant therapy, and to share his insights on the evolving role of ADCs and major challenges ahead. 
ESMO China–International Dialogue | Meeting at the Summit: How China’s Innovative ADCs sac-TMT and A166 Are Reshaping the Breast Cancer Treatment Landscape 

ESMO China–International Dialogue | Meeting at the Summit: How China’s Innovative ADCs sac-TMT and A166 Are Reshaping the Breast Cancer Treatment Landscape 

 At the 2025 European Society for Medical Oncology (ESMO) Annual Congress, Chinese innovative drugs and clinical research drew global attention. During the meeting, Xichun Hu, Professor at Fudan University Shanghai Cancer Center, presented a Late-Breaking Abstract (LBA) detailing the pivotal phase III study in which China’s first original HER2-targeted antibody–drug conjugate (ADC), A166 (budotituzumab vedotin), successfully challenged T-DM1 in the second-line setting for HER2-positive breast cancer. Based on this study, A166 received approval from the National Medical Products Administration (NMPA) on October 17, 2025, bringing a new standard-of-care option to clinical practice. 
Lerociclib and Entinostat Regimens Now Cover the Full Treatment Spectrum of HR+/HER2− Advanced Breast Cancer: Inclusion in the New National Reimbursement List Enhances Access to “Effective, Safe, and Convenient” Therapies

Lerociclib and Entinostat Regimens Now Cover the Full Treatment Spectrum of HR+/HER2− Advanced Breast Cancer: Inclusion in the New National Reimbursement List Enhances Access to “Effective, Safe, and Convenient” Therapies

Hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer accounts for approximately 70% of all breast cancer cases. Treatment for this subtype has entered the era of precision “endocrine plus” therapy. Endocrine therapy combined with CDK4/6 inhibitors has become the standard first-line treatment for advanced disease; however, differences in efficacy and safety exist among available agents.
ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies

ILCA Roundtable | MDT: Optimizing HCC Treatment Strategies – Insights from the TALENT Series Studies

In recent years, advances in systemic therapy have offered hope for advanced liver cancer patients, but traditional single treatments remain limited, highlighting the need for new approaches. Combining systemic therapy with local treatments has become a key trend, with multidisciplinary team (MDT) collaboration now a global standard. Experts from surgery, interventional radiology, oncology, and more work together to design optimal, personalized treatment plans—from diagnosis and strategy development to timing of therapy and long-term follow-up.